Kestra Medical Technologies (NASDAQ:KMTS) Stock: Insider Traci Umberger Sells 100,000 Shares

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Traci Umberger sold 100,000 shares of the firm’s stock in a transaction dated Wednesday, October 21st. The shares were sold at an average price of $27.18, for a total transaction of $2,718,000.00. Following the completion of the sale, the insider owned 195,825 shares of the company’s stock, valued at $5,322,523.50. This trade represents a 33.80% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Kestra Medical Technologies Price Performance

Kestra Medical Technologies stock traded up $1.01 during mid-day trading on Thursday, reaching $28.32. The company had a trading volume of 739,134 shares, compared to its average volume of 349,841. The stock’s 50-day simple moving average is $26.40 and its 200-day simple moving average is $23.73. Kestra Medical Technologies, Ltd. has a 1 year low of $17.34 and a 1 year high of $30.00. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.69 and a quick ratio of 4.69. The company has a market capitalization of $1.69 billion, a P/E ratio of -10.61 and a beta of 0.51.

Kestra Medical Technologies (NASDAQ:KMTS) last announced its quarterly earnings results on Monday, September 14th. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.61) by ($0.14). Kestra Medical Technologies had a negative return on equity of 63.83% and a negative net margin of 140.43%. The firm had revenue of $30.97 million for the quarter. On average, equities analysts predict that Kestra Medical Technologies, Ltd. will post -2.45 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. JPMorgan Chase & Co. initiated coverage on shares of Kestra Medical Technologies in a research report on Monday, August 10th. They set an “overweight” rating and a $30.00 target price for the company. Royal Bank Of Canada set a $30.00 price target on shares of Kestra Medical Technologies in a research report on Tuesday, September 15th. Weiss Ratings raised shares of Kestra Medical Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, September 16th. Wall Street Zen downgraded Kestra Medical Technologies from a “hold” rating to a “sell” rating in a research report on Saturday, September 12th. Finally, Oppenheimer began coverage on Kestra Medical Technologies in a research note on Tuesday, July 21st. They issued a “market perform” rating on the stock. Five investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $29.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in KMTS. Quantinno Capital Management LP purchased a new stake in shares of Kestra Medical Technologies during the first quarter worth about $431,000. California State Teachers Retirement System lifted its stake in shares of Kestra Medical Technologies by 39.2% during the first quarter. California State Teachers Retirement System now owns 27,835 shares of the company’s stock valued at $555,000 after buying an additional 7,844 shares during the period. Spartan Wealth Advisory Services LLC purchased a new position in shares of Kestra Medical Technologies during the first quarter valued at approximately $603,000. Corient Private Wealth LP boosted its position in Kestra Medical Technologies by 284.2% during the second quarter. Corient Private Wealth LP now owns 60,614 shares of the company’s stock worth $1,542,000 after acquiring an additional 44,839 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its position in Kestra Medical Technologies by 47.2% during the first quarter. Bank of New York Mellon Corp now owns 70,113 shares of the company’s stock worth $1,397,000 after acquiring an additional 22,471 shares during the last quarter.

Kestra Medical Technologies Company Profile

Kestra Medical Technologies, Inc is a medical technology company focused on developing and commercializing wearable solutions for patients at risk of sudden cardiac arrest. Its primary product is the ASSURE wearable cardioverter defibrillator, a wearable device designed to continuously monitor a patient’s heart rhythm and deliver a therapeutic shock when clinically necessary.

The company’s platform combines cardiac monitoring, arrhythmia detection and defibrillation capabilities in a wearable system intended for use outside the hospital.